William Blair analyst Raju Prasad maintained a Buy rating on Taysha Gene Therapies (TSHA – Research Report) yesterday. The company’s shares closed last Tuesday at $16.15, close to its 52-week low of $15.50.
According to TipRanks.com, Prasad is a 4-star analyst with an average return of 6.5% and a 43.1% success rate. Prasad covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Crispr Therapeutics AG, and Rocket Pharmaceuticals.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Taysha Gene Therapies with a $44.14 average price target, implying a 175.9% upside from current levels. In a report issued on October 19, Morgan Stanley also initiated coverage with a Buy rating on the stock with a $39.00 price target.
See today’s best-performing stocks on TipRanks >>
Taysha Gene Therapies’ market cap is currently $612.3M and has a P/E ratio of -5.40. The company has a Price to Book ratio of 3.24.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. It is advancing a deep and sustainable product portfolio of 18 gene therapy product candidates, with exclusive options to acquire four additional development programs. Its product candidates include TSHA-101, TSHA-118, TSHA-102, TSHA-103, and TSHA-104.
Read More on TSHA:
- Facebook (FB) Received its Third Buy in a Row
- Compagnie Générale des Établissements Michelin (MGDDF) Gets a Hold Rating from Goldman Sachs
- Barclays Keeps a Buy Rating on Compagnie Générale des Établissements Michelin (MGDDF)
- Analysts’ Opinions Are Mixed on These Financial Stocks: Deutsche Bank AG (DB) and UBS Group AG (UBS)
- Zurn Water Solutions (ZWS) Received its Third Buy in a Row
